Arshad Khanani, MD, describes the retrospective analysis he presented at the American Society of Retina Specialists annual meeting—looking at patients who underwent vitrectomy for full-thickness macular hole in one eye and ocriplasmin in the fellow eye. Dr. Khanani outlines the results of this study and the key findings learned by the investigators. He describes how early intervention with ocriplasmin can help avoid the development of full-thickness macular holes.
This video contains a physician’s narrative of his experience using ocriplasmin to treat Vitreomacular Adhesion in his practice. Any discussion by the presenter of an unlabeled use of JETREA has not received the approval of the FDA or ThromboGenics, and the opinions expressed by the physician regarding the optimal use of ocriplasmin are not necessarily those of ThromboGenics.
Ocriplasmin (Jetrea) is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion. Click the link below for the full prescribing information.
Macular Hole • Ocriplasmin • ThromboGenics